A number of FLT3 TKIs have been or are being investigated in allo-HSCT settings for FLT3-ITD AML, including sorafenib (144, 145), midostaurin, quizartinib, crenolanib, and gilteritinib (144–149). The gene discussed is FLT3; the disease is acute myeloid leukemia.